Collectively, these data indicate that PD-1 promoter methylation and other epigenetic modifications could constitute key reasons for the failure of immune checkpoint inhibitors, but these potential mechanisms have yet to be investigated systematically in CRC. Here, PDCD1 is linked to colorectal carcinoma.